Primary endoresection of choroidal melanoma: 10-year experience results
DOI: 10.32364/2311-7729-2025-25-Suppl-14
A.A. Yarovoy, I.M. Gorshkov, V.A. Yarovaya, V.I. Miroshnikov, D.P. Volodin
S. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russian Federation
Aim: to present 10-year experience results in choroidal melanoma (CM) management by primary endoresection (ER).
Materials and Methods: 35 patients (35 eyes) with CM aged from 30 to 75 years (mean — 58 years) were treated by the primary ER method from 2014 to 2024. There were 9 (26%) women and 26 (74%) men among them. According to the international TNM classification (AJCC) (2017), 11 (31%) and 24 (69%) patients had CMs of T3 and T2 stages, respectively. No CM metastases were detected in any patient at the time of treatment. Before the treatment, the tumor thickness ranged from 6.0 to 11.6 mm (mean — 8.2 mm), and its basal diameter ranged from 7.8 to 13.9 mm (mean — 11 mm). The average follow-up was 69 months.
Results: histological examination of the ER-related MC specimens revealed two variants of melanocyte phenotypes: spindle cell (23 cases) and mixed epithelioid-spindle cell (12 cases) ones. After the treatment, the best corrected visual acuity ranged from light perception with incorrect light projection to 0.8 (mean — 0.15). In a long-term follow-up (3 — 18 months, mean — 73 months), complications were reported in 62% of patients. In a long-term follow-up (3 — 18 months), complications were reported in 62% of patients. Posterior subcapsular cataract was the most common complication (n=15, 43%). In 91% of cases (n=32), the treated eye was preserved.
Conclusion: our long-term experience of CM endoresection proves the efficacy, safety and feasibility of wider application of the method preventing enucleation without increasing a risk of metastasis in patients with "large" CMs.
Keywords: uveal melanoma, primary endoresection, vitreoretinal surgery, choroidal melanoma, large tumors.
For citation: Yarovoy A.A., Gorshkov I.M., Yarovaya V.A., Miroshnikov V.I., Volodin D.P. Primary endoresection of choroidal melanoma: 10-year experience results. Russian Journal of Clinical Ophthalmology. 2025;25(Special Issue):98–103 (in Russ.). DOI: 10.32364/2311-7729-2025-25-Suppl-14
About the authors:
Andrey A. Yarovoy — Dr. Sc. (Med.), Head of the Department of Ophthalmo-oncology and Radiotherapy, S. Fyodorov Eye
Microsurgery Federal State Institution; 59a, Beskudnikovskii blvd., Moscow, 127486, Russian Federation; ORCID iD 0000-0003-2219-7054
Il'ya M. Gorshkov — C. Sc. (Med.), Head of the Department of Vitreoretinal Surgery, S. Fyodorov Eye Microsurgery Federal State Institution; 59a, Beskudnikovskii blvd., Moscow, 127486, Russian Federation; ORCID iD 0000-0002-9370-5549
Vera A. Yarovaya — C. Sc. (Med.), Ophthalmologist, Department of Ophthalmo-oncolology and Radiotherapy, S. Fyodorov Eye Microsurgery Federal State Institution; 59a, Beskudnikovskii blvd., Moscow, 127486, Russian Federation; ORCID iD 0000-0001-8937-7450
Vladimir I. Miroshnikov — Ophthalmologist, Postgraduate Student of the Department of Ophthalmo-oncology and Radiotherapy, S. Fyodorov Eye Microsurgery Federal State
Institution; 59a, Beskudnikovskii blvd., Moscow, 127486, Russian Federation; ORCID iD 0009-0006-4839-1428
Denis P. Volodin — C. Sc. (Med.), Ophthalmologist, Junior Scientific Officer, S. Fyodorov Eye Microsurgery Federal State Institution; 59a, Beskudnikovskii blvd., Moscow, 127486, Russian Federation; ORCID iD 0000-0002-3660-7803
Contact information: Vladimir I. Miroshnikov, e-mail: vladimir.miroshnikov@icloud.com
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 20.12.2024.
Revised 10.01.2025.
Accepted 30.01.2025.
2. Shields C.L., Shields J.A. Ocular melanoma: relatively rare but requiring respect. Clin Dermatol. 2009;27(1):122–133. DOI: 10.1016/j.clindermatol.2008.09.010
3. Щеголев А.И., Туманова У.Н., Кармазановский Г.Г. Восьмое издание Международной TNM-классификации злокачественных опухолей печени. Медицинская визуализация. 2017;(6):41–48. DOI: 10.24835/1607-0763-2017-6-41-48Shchegolev A.I., Tumanova U.N., Karmazanovsky G.G. Eighth Edition of the International TNM Classification of Malignant Tumors of the Liver. Medical Visualization. 2017;(6):41–48 (in Russ.). DOI: 10.24835/1607-0763-2017-6-41-48
4. Naseripour M., Jaberi R., Sedaghat A. et al. Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate. J Contemp Brachytherapy. 2016;8(1):66–73. DOI: 10.5114/jcb.2016.57818
5. Бровкина А.Ф., Стоюхина А.С., Чесалин И.П. Брахитерапия меланом хориоидеи и вторичная энуклеация. Офтальмологические ведомости. 2014;7(2):69–77. DOI: 10.17816/OV2014269-77Brovkina A.F., Stoyukhina A.S., Chesalin I.P. Brachytherapy of choroidal melanomas and secondary enucleation. Ophthalmology reports. 2014;7(2):69–77 (in Russ.). DOI: 10.17816/OV2014269-77
6. Bechrakis N.E., Blatsios G., Haas G. Kurzer historischer Rückblick der Strahlentherapie intraokularer Tumoren [Short Review of the History of Radiotherapy for Intraocular Tumours]. Klin Monbl Augenheilkd. 2015;232(7):834–837 (in German). DOI: 10.1055/s-0035-1546187
7. Brewington B.Y., Shao Y.F., Davidorf F.H., Cebulla C.M. Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions. Clin Ophthalmol. 2018;12:925–934. DOI: 10.2147/OPTH.S129645
8. Seibel I., Riechardt A.I., Heufelder J. et al. Adjuvant Ab Interno Tumor Treatment After Proton Beam Irradiation. Am J Ophthalmol. 2017;178:94–100. DOI: 10.1016/j.ajo.2017.03.027
9. McCannel T.A., Kamrava M., Demanes J. et al. 23-mm iodine-125 plaque for uveal melanoma: benefit of vitrectomy and silicone oil on visual acuity. Graefes Arch Clin Exp Ophthalmol. 2016;254(12):2461–2467. DOI: 10.1007/s00417-016-3485-9
10. Cho Y., Chang J.S., Yoon J.S. et al. Ruthenium-106 Brachytherapy with or without Additional Local Therapy Shows Favorable Outcome for Variable-Sized Choroidal Melanomas in Korean Patients. Cancer Res Treat. 2018;50(1):138–147. DOI: 10.4143/crt.2016.391
11. Бойко Э.В., Жоголев К.С., Иванов П.И. и др. Опыт лечения пациентов с меланомой хориоидеи с помощью радиохирургической установки «Гамма-нож». Современные технологии в офтальмологии. 2016;1:40–43.Boyko E.V., Zhogolev K.S., Ivanov P.I. et al. Experience of treating patients with choroidal melanoma using the Gamma Knife radiosurgical unit. Modern technologies in ophthalmology. 2016;1:40–43 (in Russ.).
12. Яровой А.А., Горшков И.М., Голубева О.В. Эндовитреальное удаление увеальной меланомы: пятилетний опыт. Эффективная фармакотерапия. 2016;39:64–67.Yarovoy A.A., Gorshkov I.M., Golubeva O.V. Endovitreal removal of uveal melanoma: five-year experience. Effective pharmacotherapy. 2016;39:64–67 (in Russ.).
13. Яровой А.А., Горшков И.М., Коробов Е.Н., Яровая В.А. Способ эндовитреального удаления меланомы хориоидеи с профилактикой метастазирования и тромбоэмболии. Патент на изобретение № RU 2 688 966 C1. Опубл. 23.05.2019.Yarovoy A.A., Gorshkov I.M., Korobov E.N., Yarovaya V.A. Method of endovitreal removal of choroidal melanoma with prevention of metastasis and thromboembolism. Patent for invention No. RU 2 688 966 C1. Published 23.05.2019. (in Russ.).
14. Rao Y.J., Sein J., Badiyan S. et al. Patterns of care and survival outcomes after treatment for uveal melanoma in the post-coms era (2004-2013): a surveillance, epidemiology, and end results analysis. J Contemp Brachytherapy. 2017;9(5):453–465. DOI: 10.5114/jcb.2017.70986
15. Бровкина А.Ф. Локальное лечение меланом хориоидеи: возможности и ограничения. Вестник офтальмологии. 2018;134(4):52–60.Brovkina A.F. Local treatment of choroidal melanoma: possibilities and limitations. Russian Annals of Ophthalmology. 2018;134(4):52–60 (in Russ.).
16. Damato B., Groenewald C., McGalliard J., Wong D. Endoresection of choroidal melanoma. Br J Ophthalmol. 1998;82(3):213–218. DOI: 10.1136/bjo.82.3.213
17. Hadden P.W., Hiscott P.S., Damato B.E. Histopathology of eyes enucleated after endoresection of choroidal melanoma. Ophthalmology. 2004;111(1):154–160. DOI: 10.1016/j.ophtha.2003.05.007
18. Caminal J.M., Mejia K., Masuet-Aumatell C. et al. Endoresection versus iodine-125 plaque brachytherapy for the treatment of choroidal melanoma. Am J Ophthalmol. 2013;156(2):334–342.e1. DOI: 10.1016/j.ajo.2013.03.036
19. Karkhaneh R., Chams H., Amoli F.A. et al. Long-term surgical outcome of posterior choroidal melanoma treated by endoresection. Retina. 2007;27(7):908–914. DOI: 10.1097/IAE.0b013e31802fa2db
20. Vidoris A.A.C., Maia A., Lowen M. et al. Outcomes of primary endoresection for choroidal melanoma. Int J Retina Vitreous. 2017;3:42. DOI: 10.1186/s40942-017-0096-5
21. García-Arumí J., Sararols L., Martinez V., Corcostegui B. Vitreoretinal surgery and endoresection in high posterior choroidal melanomas. Retina. 2001;21(5):445–452. DOI: 10.1097/00006982-200110000-00005
This work is licensed under a Creative Commons «Attribution» 4.0 License.
